• BFH772 (VEGFR2 inhibitor): Protocols, Use, and QC Guidance

  2026-04-25

  BFH772 is a potent, selective VEGFR2 inhibitor for researchers targeting VEGFR2-mediated angiogenesis, particularly in tumor growth models. It is not suitable for workflows requiring water-soluble compounds or broad-spectrum kinase inhibition due to its defined solubility and selectivity profiles.

• Phosbind Biotin LC: Practical Guide for Phosphorylated Prote

  2026-04-24

  Phosbind Biotin LC enables sensitive, sequence-independent detection of phosphorylated proteins in Western Blot workflows. It provides a reliable alternative to phospho-specific antibodies, particularly where sequence context is unknown or such antibodies are unavailable. This reagent should not be used in aqueous-only protocols or workflows requiring long-term stock solution storage.

• Intranasal Epinephrine in Dogs: Pharmacokinetics and Heart R

  2026-04-24

  This study evaluates the pharmacokinetics and cardiac response of intranasal versus intramuscular epinephrine in canine models. The findings demonstrate rapid systemic absorption and reduced heart rate impact with intranasal delivery, supporting its potential as an alternative emergency intervention in anaphylaxis.

• Integrative Protocols for (-)-Epinephrine (+)-bitartrate in

  2026-04-23

  Explore the nuanced use of Epinephrine Bitartrate as a non-selective adrenergic receptor agonist in translational cardiology and neurobiology. This article uniquely bridges high-resolution protocol design and comparative evidence, providing actionable insights for advanced sympathetic nervous system research.

• Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Technica

  2026-04-23

  The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) safeguards protein samples during extraction by inhibiting a broad range of endogenous proteases without compromising mass spectrometry compatibility. It is ideal for workflows requiring robust protein degradation prevention but is not suitable for metalloproteinase inhibition unless supplemented with EDTA.

• DDX21-NAT10-ac4C Axis Drives Metastasis in Colorectal Cancer

  2026-04-22

  This study uncovers how DDX21 enhances colorectal cancer metastasis and angiogenesis by upregulating NAT10, which increases ac4C mRNA modification and stability of pro-metastatic transcripts. The findings provide a mechanistic link between RNA modification and tumor progression, highlighting the DDX21/NAT10 axis as a potential therapeutic target.

• Directed Induction of RV-like Cardiomyocytes from hPSCs: Adv

  2026-04-22

  Saito et al. present a refined differentiation protocol enabling the specific induction of right ventricular (RV)-like cardiomyocytes from human pluripotent stem cells (hPSCs). This work clarifies chamber-specific cardiac lineage allocation and creates a platform for disease modeling of RV pathologies, highlighting methodological advances relevant for cardiac research.

• Proteinase K in Translational Workflows: Mechanisms, Metrics

  2026-04-21

  This expert article dissects the mechanistic and strategic value of Proteinase K—a recombinant broad-spectrum serine protease—for translational researchers. By integrating recent findings on fungal EV biology, rigorous protocol parameters, and competitive market analysis, we highlight how APExBIO’s Proteinase K (K1037) delivers precision and workflow reliability for advanced DNA isolation, protein hydrolysis, and contaminant removal. This piece moves beyond product listings by connecting enzymatic function to emerging research demands and clinical implications.

• DIDS: Mechanistic Leverage for Translational Chloride Channe

  2026-04-21

  Explore how DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) empowers translational research by elucidating chloride channel mechanisms, bridging foundational ion transport discoveries to high-impact cancer, neuroprotection, and vascular studies. This article contextualizes DIDS through recent breakthroughs on metastasis, clarifies strategic workflows, and highlights APExBIO’s role in providing rigorously benchmarked research reagents.

• ONX-0914 (PR-957): Decoding Immunoproteasome Inhibition in A

  2026-04-20

  Explore the precise mechanism and translational impact of ONX-0914 (PR-957) in immunoproteasome inhibition. This article uniquely dissects recent landmark findings to guide advanced autoimmune research applications.

• Open-Tubular CEC for β2-Adrenergic Receptor–Drug Binding Ana

  2026-04-20

  This study introduces an efficient open-tubular capillary electrochromatography (CEC) approach to determine binding constants between the β2-adrenergic receptor and several drugs. The method reduces protein consumption, improves experimental throughput, and offers reproducible affinity data, with implications for drug screening and adrenergic signaling research.

• AMPK Inhibits ULK1: Redefining Autophagy Control Under Energ

  2026-04-19

  This study overturns the prevailing view that AMPK universally induces autophagy by demonstrating that AMPK actually suppresses ULK1 activity and autophagy initiation during glucose starvation. The findings prompt a significant revision of autophagy signaling models and suggest new strategies for dissecting autophagy regulation using selective kinase inhibitors.

• Macrophage-Amphiregulin Drives Myofibroblast Transition in O

  2026-04-18

  This study uncovers a macrophage-driven mechanism in Staphylococcus aureus osteomyelitis, where amphiregulin secretion induces myofibroblast transition in adipogenic precursors, leading to vascular constriction and impaired bacterial clearance. Targeting the AREG/EGFR/mTOR/YAP axis offers a new strategy to enhance antibiotic efficacy in chronic bone infections.

• Carfilzomib (PR-171): Proteasome Inhibition Redefined for Ra

  2026-04-17

  Discover how Carfilzomib (PR-171) advances proteasome inhibition in cancer research by enabling multi-modal cell death and enhancing radiosensitivity, with a deep dive into assay optimization and translational impact.

• Abiraterone Acetate: CYP17 Inhibitor Workflows in 3D Prostat

  2026-04-16

  Abiraterone acetate, a potent CYP17 inhibitor, is redefining the study of castration-resistant prostate cancer by enabling robust, reproducible experiments in both 2D and patient-derived 3D spheroid cultures. This article translates the latest evidence and hands-on troubleshooting into actionable workflows for prostate cancer researchers.

11303 records 1/754 page Next 12345 下5页 Last page